JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: In Vitro Activity

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2115

Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)

Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2754

In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources

In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources.  Lead author: Antony Pfaffle, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2117

Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections

Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections.  Lead author: Rodrigo Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2173

In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)

In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020).  Lead author: Leonard Duncan, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2162

Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022

Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022.  Lead author: S.J. Ryan Arends, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2159

Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints

Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints.  Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #P2113

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022).  Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #1292

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program by JM Maher, MD Huband, CG Blankers, S Puttagunta, SI Aronin, and M Castanheira in J Antimicrob Chemother 78(4): 2023, dkad099.

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)

Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020) by SJR Arends, D Butler, N Scagarella-Oman, M Castanheira, and RE Mendes in Antimicrob Agents Chemother 67(4): 2023, e0152522.

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme. Lead author: Michael Huband. ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions

In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions. Lead Author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021)

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum. Lead author: Dee Shortridge. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates. Lead author: Timothy Doyle. ECCMID, April 15-18, Copenhagen.

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres. Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, Copenhagen.

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021)

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022)

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. Lead Author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) by HS Sader, M Castanheira, JH Kimbrough, V Kantro, RE Mendes in J. Antimicrob. Chemother. 5(3):2023, dlad032.

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018−2022)

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug resistant Enterobacterales from United States Medical Centers (2018−2022) by HS Sader, RE Mendes, L Duncan, JH Kimbrough, CG Carvalhaes, and M Castanheira in Diagn Microbiol Infect Dis 2023; 106, 115945.

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with complicated urinary tract infections

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with complicated urinary tract infections by HS Sader, CG Carvalhaes, MD Huband, RE Mendes, and M Castanheira in Eur J Clin Microbiol Infect Dis. 2023; 42(2), 453-459.

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections by JM Maher, RE Mendes, HK Huynh, EA Porsch, JW St Greme III, P Yagupsky, and J Bradley in Pediatr Infect Dis 2023; 42(3), 206-2011.

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers by HS Sader, RE Mendes, JH Kimbrough, V Kantro, and M Castanheira in Open Forum Infect Dis 2023; 10 (2), ofad058.

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021) by HS Sader, RE Mendes, CG Carvalhaes, JH Kimbrough, M Castanheira in Open Forum Infect Dis 10.2 (2023), ofad046.

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms by M Castanheira, J Lindley, TB Doyle, AP Davis, HS Sader in Int J Antimicrob 61 (2023), 106698.

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020) by HS Sader, M Castanheira, LR Duncan, RE Mendes in Diagn Microbiol Infect Dis 105:1 (2023), 115820.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals. Lead Author: Rodrigo E. Mendes. Presented at IDWeek 2022, October 19-23, Washington DC.

In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020)

In vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020) by Mendes RM, Hubler C, Kimbrough JH, Critchley I, Cotroneo N, Castanheira in Antimicrob. Agents Chemother. 66:10 (2022); aac.01214-22.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States Lead Author: SJ Ryan Arends presented at IDWeek 2022, October 19-23, Washington DC

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals. Lead author: Rodrigo Mendes. Presented at IDWeek 2022. October 19-21, 2022. Washington DC.

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units in US Medical Centers (2010–2019)

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units
in US Medical Centers (2010–2019). Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021. Lead author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021)

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals. Lead Author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021)

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). Lead Author: HS Sader at IDWeek 2022, October 19-23, Washington DC.

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type. Lead Author: Mike Huband, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States. Lead author: SJ Ryan Arends. IDWeek 2022. October 19-21. Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the
United States. Lead Author: Rodrigo Mendes. IDWeek 2022. October 19-21, 2022. Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021)

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Activity of Meropenem-Vaborbactam and Comparators Against Enterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States

Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric Patients from US Medical Centers (2020–2021)

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric
Patients from US Medical Centers (2020–2021). Lead author: Helio Sader. IDWeek 2022. October 19-21. Washington DC.